MIRUM PHARMACEUTICALS INC's ticker is MIRM and the CUSIP is 604749101. A total of 52 filers reported holding MIRUM PHARMACEUTICALS INC in Q3 2020. The put-call ratio across all filers is - and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $715,551 | +32.9% | 22,644 | +8.8% | 0.00% | – |
| Q2 2023 | $538,356 | +188.1% | 20,810 | +167.5% | 0.00% | – |
| Q1 2023 | $186,851 | +31.6% | 7,779 | +6.8% | 0.00% | – |
| Q4 2022 | $141,980 | -7.2% | 7,281 | 0.0% | 0.00% | – |
| Q3 2022 | $153,000 | +19.5% | 7,281 | +10.6% | 0.00% | – |
| Q2 2022 | $128,000 | +2033.3% | 6,583 | +2193.7% | 0.00% | – |
| Q1 2022 | $6,000 | +20.0% | 287 | 0.0% | 0.00% | – |
| Q4 2021 | $5,000 | -16.7% | 287 | 0.0% | 0.00% | – |
| Q3 2021 | $6,000 | 0.0% | 287 | -18.5% | 0.00% | – |
| Q2 2021 | $6,000 | -40.0% | 352 | -28.7% | 0.00% | – |
| Q1 2021 | $10,000 | +11.1% | 494 | 0.0% | 0.00% | – |
| Q4 2020 | $9,000 | 0.0% | 494 | 0.0% | 0.00% | – |
| Q3 2020 | $9,000 | -43.8% | 494 | -39.6% | 0.00% | – |
| Q2 2020 | $16,000 | +45.5% | 818 | 0.0% | 0.00% | – |
| Q1 2020 | $11,000 | -21.4% | 818 | +48.5% | 0.00% | – |
| Q4 2019 | $14,000 | – | 551 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Frazier Life Sciences Management, L.P. | 6,470,392 | $204,464,387 | 13.58% |
| NEA Management Company, LLC | 2,186,243 | $69,085,279 | 5.34% |
| TANG CAPITAL MANAGEMENT LLC | 1,137,107 | $35,932,581 | 5.07% |
| BOONE CAPITAL MANAGEMENT LLC | 389,791 | $12,317,396 | 3.89% |
| Highlander Partners, L.P. | 122,980 | $3,886,168 | 3.84% |
| BVF INC/IL | 4,370,024 | $138,092,758 | 3.72% |
| Prosight Management, LP | 353,508 | $11,170,853 | 3.54% |
| Novo Holdings A/S | 1,500,000 | $47,400,000 | 3.50% |
| Nicholas Investment Partners, LP | 1,199,366 | $37,899,966 | 2.83% |
| Eventide Asset Management | 3,958,579 | $125,091,097 | 2.25% |